Inside ICH: ICH Implementation Support - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Inside ICH: ICH Implementation Support
ICH Q8, Q9, and Q10 support and implications for the future.


Pharmaceutical Technology
Volume 36, Issue 2, pp. 52-53

Acknowledgments

The topics described in this article have been developed and discussed by members of the ICH Quality Implementation Working Group, namely: Jean-Louis Robert (rapporteur), Diana Amador-Toro, Robert G. Baum, Nicholas Cappuccino, David Cockburn, Georges France, Richard L. Friedman, Nigel Hamilton, Sabine Kopp, Hirotada Nagai, Yukio Hiyama, Takao Kyohara, Fusashi Ishikawa, Sabine Kopp, Urs Kopp, Akira Kusai, Yoshihiro Matsuda, Motoaki Mitsuki, Elaine Morefield, Jacques Morénas, Masatoshi Morisue, Markus-Peter Müller, Tamiji Nakanishi, Moheb Nasr, Kazuhiro Okochi, Anthony Ridgway, Rachael Roehrig, Stephan Rönninger, Swroop Sahota, Hideki Sasaki, Tetsuhito Takarada, Shigheki Tamura, Krishnan Tirunellai, Mats Welin, and Jean M. Wyvratt.

Stephan Rönninger is deputy topic leader for EFPIA in the ICH Q–IWG and head of External Collaboration Europe/Japan/CEMA at F. Hoffmann-La Roche. Sabine Scheitlin is operational support manager at F. Hoffmann-La Roche, both based in Basel, Switzerland, tel. +41 61 688 69 74.

References

1. ICH Steering committee (Brussels, Belgium, 2003).

2. ICH, Q8, Q9, Q10 Implementation, Question and Answers (Q&A), November 2010 ( http://www.ich.org/)

3. ICH, Q8, Q9, Q10 Implementation, Training material, November 2010 ( http://www.ich.org/).

4. ICH, Q8, Q9, Q10 Implementation, Points to Consider, December 2011 ( http://www.ich.org/)

5. FDA, Guidance for Industry: Process Validation: General Principles and Practices (Rockville, MD, 2011).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here